Crystalline form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide
US-2023242515-A1 · Aug 3, 2023 · US
Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide
US12565487B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12565487-B2 |
| Application number | US-202318134564-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 13, 2023 |
| Priority date | Mar 30, 2017 |
| Publication date | Mar 3, 2026 |
| Grant date | Mar 3, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-5N-(methyl-d3)pyridazine-3-carboxamide of the formula:Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.
First claim
Opening claim text (preview).
What is claimed is: 1 . A compound selected from the following: (a) one of the following five compounds: (b) a salt of any one of the compounds in (a); or (c) a hydrate of any one of the compounds in (a), or a hydrate of a salt of any one of the compounds in (a). 2 . The compound according to claim 1 , which is: or a hydrate of 3 . The compound according to claim 1 , which is: or a hydrate of 4 . The compound according to claim 1 , which is: or an H 2 SO 4 salt of or an HCl salt of 5 . The compound according to claim 1 , which is:
Assignees
Inventors
Classifications
Crystalline forms, e.g. polymorphs · CPC title
- C07D249/08Primary
1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles · CPC title
Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen · CPC title
Diamines · CPC title
Isotopically modified compounds, e.g. labelled · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12565487B2 cover?
- The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-5N-(methyl-d3)pyridazine-3-carboxamide of the formula:Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.
- Who is the assignee on this patent?
- Bristol Myers Squibb Co
- What technology area does this patent fall under?
- Primary CPC classification C07D249/08. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 03 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).